BiomX, Inc. (PHGE)
| Market Cap | 22.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.99M |
| Shares Out | 31.24M |
| EPS (ttm) | -1.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,360 |
| Open | 0.776 |
| Previous Close | 0.764 |
| Day's Range | 0.694 - 0.780 |
| 52-Week Range | 0.640 - 6.730 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 10.97 (+1,413.1%) |
| Earnings Date | May 11, 2022 |
About PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinic...
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for PHGE stock is "Buy." The 12-month stock price forecast is 10.97, which is an increase of 1,413.10% from the latest price.
News
BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed
BiomX Inc (NYSE: PHGE) announced a corporate restructuring plan to focus its resources and extend the cash runway. The company had $55.7 million in cash, cash equivalents, short-term deposits, and a $15...
BiomX Announces Corporate Restructuring
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...
BiomX Announces Publication in the Journal, Bioinformatics
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis...
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...
BiomX Presenting at Three Upcoming Investor Conferences
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Presenting at Three Upcoming Investor Conferences
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage thera...
BiomX Presenting at Two Upcoming Conferences in November
Jefferies London Healthcare Conference on November 18 - 19, 2021
BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update
Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022
Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a Turnaround
BiomX Inc. (PHGE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...
BiomX's Acne Vulgaris Treatment Fails To Top Vehicle Treatment Cohort
BiomX Inc (NYSE: PHGE) announced results from its Phase 2 study to assess BX001 to improve the appearance of skin in acne-prone subjects. A statistically significant improvement from baseline was obser...
BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study
12-Week Study of BX001 Meets Safety and Tolerability Endpoints
BiomX Enters Agreement Granting Maruho Co. A right Of First Offer To License BiomX's Atopic Dermatitis Product Candid...
BiomX Inc. (NYSE: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today t...
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and eng...
BiomX to Present at Upcoming September Investor Conferences
BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and en...
BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update
Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023
BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021
NESS ZIONA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therap...
BiomX Inc. Announces $15 Million Registered Direct Offering
NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therap...
BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Vir...
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...
BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...
BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...
BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease
Live webinar to be held on Wednesday, May 26th at 8:00 AM EDT Live webinar to be held on Wednesday, May 26th at 8:00 AM EDT